Author:
Scheulen M. E.,Kramer B.,Skorzec M.,Reich W. K.
Publisher
Springer Berlin Heidelberg
Reference11 articles.
1. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3: 1583–1589
2. Kartner N, Riordan JR, Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell Unes. Science 221: 1285–1288
3. Kokenberg E, van der Steuyt K, Löwenberg B, Sonneveld P (1987) Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. In: Büchner T, Schellong G, Hiddemann W, Urbanitz D, Ritter J (eds) Acute leukemias. Prognostic factors and treatment strategies. Springer, Berlin Heidelberg New York, pp 283–287 (Haematology and Blood Transfusion, vol 30)
4. Ling V, Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103–116
5. Ma DDF, Scurr RD, Davey RA, Mackertich SM, Harman DH, Dowden G, Isbister JP, Bell DR (1987) Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet 1: 135–137